Author

Martine De Vos

EARLY FIBROSTENOSIS IN CROHN’S DISEASE IS ASSOCIATED WITH MULTIPLE SUSCEPTIBILITY LOCI ON IMMUNOCHIP ANALYSIS

Tom Holvoet, Peter Bossuyt, Isabelle Cleynen, Isabelle De Kock, Pieter Hindryckx, Severine Vermeire, Debby Laukens, Martine De Vos

Evolution of endoscopic lesions in patients admitted for acute severe ulcerative colitis responding to infliximab or cyclosporine: sub-study from the CYSIF trial

David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jerome Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, Jacques Moreau, Aurelien Amiot, Laurent Beaugerie, Elena Ricart, Olivier Dewit, Antonio López San Román, Mathurin Fumery, Franck Carbonnel, Anthony Buisson, Benoit Coffin, Xavie

HIGHER EARLY VEDOLIZUMAB CONCENTRATIONS AT TROUGH ARE ASSOCIATED WITH ENDOSCOPIC REMISSION AT 26 WEEKS IN CROHN’S DISEASE

Mark Lowenberg, Sophie Berends, Severine Vermeire, Ron Mathôt, Esmé Clasquin, Frank Hoentjen, Peter Bossuyt, Philippe Van Hootegem, Martine De Vos, Geert R. D'Haens, Filip Baert

Integrin expression changes on the T cell subsets influence the response to vedolizumab in inflammatory bowel disease patients

Cara De Galan, Sophie Van Welden, Simon Bos, Simon Tavernier, Triana Lobaton Ortega, Gerard Gonzales, Wouter Van Moerkercke, Beatrijs Strubbe, Harald Peeters, Elisabeth Macken, Martine De Vos, Debby Laukens, Pieter Hindryckx

SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY IBD PATIENTS: A REAL-LIFE MULTICENTRIC COHORT STUDY

Cara De Galan, Harald Peeters, Francisco Mesonero Gismero, Marie Truyens, Ainara Elorza, Paola Torres, Liv Vandermeulen, Aranzazu Jauregui Amezaga, Rocío Ferreiro-Iglesias, Yamile Zabana, Tom Holvoet, Laia Peries Reverter, Jeroen Geldof, Triana Lobaton, Martine De Vos

Item 1 - 5 / 5
1